Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association
Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association
复制标题
DOI：
10.1017/s0950268813000940
复制
发表时间：
2014-02-01
影响因子：
4.2
通讯作者：
Donoghoe, M. C.
中科院分区：
文献类型：
--
作者：
Hope, V. D.;Eramova, I.;Donoghoe, M. C.
了解B型和C型肝炎的流行情况以及感染人数对于规划应对措施很重要。提取了EU/EFTA以外20个WHO欧洲地区国家的已发表HBsAg和抗-HCV患病率，以补充EU/EFTA的已发表数据。一般人群HBsAg（中位数3个中心点8%，平均5个中心点0%，7个国家）的患病率范围为1个中心点3%（乌克兰）至13%（乌兹别克斯坦），抗-HCV（中位数2个中心点3%，平均3个中心点8%，10个国家）的患病率范围为0个中心点5%（塞尔维亚、塔吉克斯坦）至13%（乌兹别克斯坦）。注射毒品的人两种感染的患病率最高（HBsAg：中位数6个中心点8%，平均8个中心点2%，13个国家;抗HCV：中位数46%，平均46%，17个国家），男性同性恋者和性工作者的患病率也升高。简单估计表明，在WHO欧洲区域，13个中心点300万（1个中心点8%）成人有HBsAg，15个中心点000万（2个中心点0%）成人有HCV RNA;在EU/EFTA国家以外，患病率较高。预防、诊断和治疗这些感染的努力需要保持和改进。本文不得以任何方式转载或重复使用，以推广任何商业产品或服务。
Knowledge of hepatitis B and C prevalence, and numbers infected, are important for planning responses. Published HBsAg and anti-HCV prevalences for the 20 WHO European Region countries outside the EU/EFTA were extracted, to complement published data for the EU/EFTA. The general population prevalence of HBsAg (median 3 center dot 8%, mean 5 center dot 0%, seven countries) ranged from 1 center dot 3% (Ukraine) to 13% (Uzbekistan), and anti-HCV (median 2 center dot 3%, mean 3 center dot 8%, 10 countries) from 0 center dot 5% (Serbia, Tajikistan) to 13% (Uzbekistan). People who inject drugs had the highest prevalence of both infections (HBsAg: median 6 center dot 8%, mean 8 center dot 2%, 13 countries; anti-HCV: median 46%, mean 46%, 17 countries), and prevalence was also elevated in men who have sex with men and sex workers. Simple estimates indicated 13 center dot 3 million (1 center dot 8%) adults have HBsAg and 15 center dot 0 million (2 center dot 0%) HCV RNA in the WHO European Region; prevalences were higher outside the EU/EFTA countries. Efforts to prevent, diagnose, and treat these infections need to be maintained and improved.This article may not be reprinted or reused in any way in order to promote any commercial products or services.